FUS and sarcoma: Furthermore, we investigate the oncogenic properties of the underlying FUS/EWSR1-TFCP2 fusions and alterations of the ALK receptor tyrosine kinase (RTK), which invariably accompany these rearrangements, and determine the fusions’ direct and indirect transcriptional effects contributing to sarcoma development.